The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 5:32 PM PT
Lakefront Biotherapeutics, formerly Galapagos, has sold its early-stage CAR-T cell therapy assets to newly formed Belgian biotech Armed Cell Therapeutics for €8 million upfront and up to $230 million in regulatory and commercial milestones.
Agilent Technologies agreed to pay $240 million in cash upfront, plus up to $30 million in milestone payments, to acquire the digital pathology software developer Proscia.
Fairmount Funds led a concurrent private placement of roughly $350 million alongside the merger with the former cell-therapy developer Alaunos Therapeutics.
Viatris will pay $36.50 per share to purchase the pain-management specialist, funding the transaction primarily from excess cash.
GE HealthCare has agreed to acquire radiopharmaceutical company Sofie Biosciences for $945 million.
The Japanese drugmaker agreed to acquire Texas-based IntraBio in a deal valued at $2 billion by reporting outlets, absorbing an asset that generated $68 million in 2025 sales according to Shionogi.
UPMC Enterprises and Ziff Capital Partners co-led the $48 million launch round for ai3Bio, formed by combining autoimmune assets from Corner Therapeutics with University of Pittsburgh spinout Novasenta.
Australian radiopharmaceutical company Telix will acquire Germany-based ITM for $1.65 billion upfront, with up to $700 million in additional regulatory and commercial milestone payments.
Novo has acquired three early-stage obesity programs from New York biotech Kallyope, expanding its metabolic pipeline beyond the GLP-1 hormone class.
Cardiometabolic biotech Marea Therapeutics will acquire Nasdaq-listed Lisata Therapeutics in an all-stock reverse merger alongside a $225 million private placement from RA Capital Management, Forbion, Third Rock Ventures, and Sofinnova Investments.
North Immunology will list on Nasdaq under ticker NRTX by merging with Aethlon Medical alongside a $180 million private placement backed by Bain Capital Life Sciences, Janus Henderson Investors, and Deep Track Capital.
Novartis triggered its acquisition option 14 months after entering an initial evaluation agreement, gaining control of technology engineered to transport large-molecule therapies across the blood-brain barrier.
GE HealthCare is considering a buyout of cancer-imaging chemical developer Sofie Biosciences for up to $1 billion, according to a report by the Financial Times.